Abstract
ABSTRACT With lifetime prevalence estimates of substance abuse among schizophrenics as high as 47.01 % there is an increasing awareness of the importance of this dual diagnosis and the global deficiencies in our knowledge about this comorbid condition. Patients with substance abuse disorders and schizophrenia are problematic from a clinical, economic, and health care systems perspective. The lack of systematic research into phenomenology, etiology, and treatment approaches (both psychotherapeutic and psychopharmacologic) has hindered the development of an adequate strategy to care for the needs of these patients. Thus, these patients place a significant burden on the mental health delivery system through chronic disability, social dysfunction, frequent rehospitalizations, and poor overall treatment compliance. The authors critically review the contemporary literature relevant to concurrent substance abuse and schizophrenia, highlight major deficiencies in our knowledge, and call for research to reduce the individual, economic, and social costs of this condition.
| Original language | English |
|---|---|
| Pages (from-to) | 321-336 |
| Number of pages | 16 |
| Journal | American Journal of Drug and Alcohol Abuse |
| Volume | 17 |
| Issue number | 3 |
| DOIs | |
| State | Published - Jan 1 1991 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Medicine (miscellaneous)
- Psychiatry and Mental health
- Clinical Psychology
- Pharmacology, Toxicology and Pharmaceutics(all)
Cite this
Substance abuse and schizophrenia : Impediments to optimal care. / Salloum, Ihsan M; Salloum, Howard B.; Salloum, Dennis C.
In: American Journal of Drug and Alcohol Abuse, Vol. 17, No. 3, 01.01.1991, p. 321-336.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Substance abuse and schizophrenia
T2 - Impediments to optimal care
AU - Salloum, Ihsan M
AU - Salloum, Howard B.
AU - Salloum, Dennis C.
PY - 1991/1/1
Y1 - 1991/1/1
N2 - ABSTRACT With lifetime prevalence estimates of substance abuse among schizophrenics as high as 47.01 % there is an increasing awareness of the importance of this dual diagnosis and the global deficiencies in our knowledge about this comorbid condition. Patients with substance abuse disorders and schizophrenia are problematic from a clinical, economic, and health care systems perspective. The lack of systematic research into phenomenology, etiology, and treatment approaches (both psychotherapeutic and psychopharmacologic) has hindered the development of an adequate strategy to care for the needs of these patients. Thus, these patients place a significant burden on the mental health delivery system through chronic disability, social dysfunction, frequent rehospitalizations, and poor overall treatment compliance. The authors critically review the contemporary literature relevant to concurrent substance abuse and schizophrenia, highlight major deficiencies in our knowledge, and call for research to reduce the individual, economic, and social costs of this condition.
AB - ABSTRACT With lifetime prevalence estimates of substance abuse among schizophrenics as high as 47.01 % there is an increasing awareness of the importance of this dual diagnosis and the global deficiencies in our knowledge about this comorbid condition. Patients with substance abuse disorders and schizophrenia are problematic from a clinical, economic, and health care systems perspective. The lack of systematic research into phenomenology, etiology, and treatment approaches (both psychotherapeutic and psychopharmacologic) has hindered the development of an adequate strategy to care for the needs of these patients. Thus, these patients place a significant burden on the mental health delivery system through chronic disability, social dysfunction, frequent rehospitalizations, and poor overall treatment compliance. The authors critically review the contemporary literature relevant to concurrent substance abuse and schizophrenia, highlight major deficiencies in our knowledge, and call for research to reduce the individual, economic, and social costs of this condition.
UR - http://www.scopus.com/inward/record.url?scp=0025887080&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025887080&partnerID=8YFLogxK
U2 - 10.3109/00952999109027556
DO - 10.3109/00952999109027556
M3 - Article
VL - 17
SP - 321
EP - 336
JO - American Journal of Drug and Alcohol Abuse
JF - American Journal of Drug and Alcohol Abuse
SN - 0095-2990
IS - 3
ER -